|
|
|
|
|
|
|
|
|
|
|
12.02.26 - 22:15
|
Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
|
|
|
Record Full-Year 2025 Total New Debt and Equity Commitments of $3.92 Billion, an Increase of 45.7% Year-over-Year
Record Full-Year 2025 Total Fundings of $2.28 Billion, an Increase of 25.9% Year-over-Year
Record Full-Year 2025 Total Investment Income of $532.5 Million, an Increase of 7.9% Year-over-Year
Record Full-Year 2025 Net Investment Income “NII” of $341.7 Million, an Increase of 4.9% Year-over-Year
Record Q4 2025 Total Gross Debt and Equity Commitments of $1.06 Billion, an Increase of 70.8% Year-over-Year
Q4 2025 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution
Conservative Balance Sheet Management with Net Leverage of 101.8% and Net Regulatory Leverage of 86.0%(1)
Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.0 Billion of Available Liquidity as of Year End
Announced a New Supplemental Cash Distribution for 2026 of $0.28 per Share, Payable over Four Quarters
Undistributed Earnings Spillover of $149.9 ...
|
|
|
|
|
10.02.26 - 19:12
|
Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029 (Business Wire)
|
|
|
Notes due 2029 Initially Assigned Ratings of Baa2 by Moody's Investors Service and a BBB- by Fitch Ratings, Inc.SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has closed an underwritten public offering of $300.0 million in aggregate principal amount of 5.350% notes due February 2029 (the “Notes”).
The Notes are unsecured and bear interest at a rate of 5.350% per year, payable semiannually, will mature on February 10, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a “make whole” premium, if applicable.
The Company expects to use the net proceeds from this offering (i) to fund investments in accordance with its investment objectives, (ii) to repay outstanding secured indebtedness under its existing financing arrangements, and (iii) for other general corporate purposes.
Goldman Sachs & Co. LLC, SMBC Nikko Securities America, Inc. and MUFG Securi...
|
|
|
|
|
10.02.26 - 12:03
|
Hercules Capital Announces New Supplemental Cash Distribution of $0.28 per Share (Business Wire)
|
|
|
The New Supplemental Cash Distribution is in Addition to the Regular Quarterly Cash Distributions and will be Distributed Equally over Four Quarters Beginning with the Fourth Quarter of 2025 Distribution Payable in March of 2026
The New Supplemental Cash Distribution of $0.07 per Share for the Fourth Quarter of 2025 is in Addition to the Regular Quarterly Cash Distribution of $0.40 per ShareSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a new supplemental cash distribution of $0.28 per share, to be distributed equally over four quarters beginning with a $0.07 per share distribution for the fourth quarter of 2025.
This $0.07 supplemental cash distributi...
|
|
|
10.02.26 - 12:03
|
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Fourth Quarter 2025 (Business Wire)
|
|
|
The Total Cash Distribution of $0.47 per Share for the Fourth Quarter 2025 is Comprised of a Base Distribution of $0.40 per Share and a New Supplemental Distribution of $0.07 per ShareSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a fourth quarter 2025 total cash distribution of $0.47 per share. The following shows the key dates of the fourth quarter 2025 distribution payment:
Record Date February 25, 2026
Payment Date March 4, 2026
Hercules' Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% to 100% of the Company's taxable quarterly income or...
|
|
|
|
|
|
|
29.01.26 - 12:06
|
Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2025 Financial Results and Conference Call (Business Wire)
|
|
|
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2025 financial results conference call for Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.
All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of our website at investor.htgc.com. Please visit the website to test your connection before the webcast. Domestic callers can access the conference call toll free by dialing +1 (800) 267-6316. International callers can access the conference call by dialing ...
|
|
|
29.01.26 - 04:21
|
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™ (Business Wire)
|
|
|
U.S. FDA Approves YUVEZZI™ as the only dual-agent, once daily presbyopia-correcting eye dropLONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and a credit facility.
The Company raised $85 million in Series B financing led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. Existing investors also participating include EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille. In addition to the Series B, Tenpoint entered into a $150 million non-dilutive senior secured term loan facility with Hercules Capital.
“We deeply appreciate the support of our strong syndicate of global, long-term investors. This financing reflects their confidence in YUVEZZI, a new differentiated option for mil...
|
|
|
27.01.26 - 14:06
|
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
|
|
|
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI --LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity.
Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA's approval of MOLBREEVI, the Company's investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity date and interest-only period remain unchanged. There are no warrants in connection with the agreement.
“In anticipation of the potential approval of MOLBREEVI later this year, Savara will be well capitalized with ~$150 million of non-dilutive capital to support launch activities,” said...
|
|
|
20.01.26 - 23:39
|
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. (Business Wire)
|
|
|
Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer
$25 million advanced at close of the amendment to refinance existing debt facilityBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the “Loan Agreement”) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene's balance sheet in preparation for its planned Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for detalimogene voraplasmid as a treatment for high-risk, Bacillus Calmette-Guérin (“BCG”)-unresponsive non-muscle invasive b...
|
|
|
|
|
|
|
|
|
04.12.25 - 16:48
|
Stop Waiting for “Rate Cuts.” Here′s How to Build an 8% Yield Portfolio Even if the Fed Holds Rates in December (24/7 Wall St.)
|
|
|
Many investors believe further interest rate cuts in December are guaranteed. Dividend stocks like Plains All American Pipeline LP (NASDAQ:PAA), Hercules Capital (NYSE:HTGC), and TORM plc (NASDAQ:TRMD) can help you build a high-yield portfolio without going into Treasuries with less attractive yields today. The Federal Reserve was shying away from cutting rates as the inflation ... Stop Waiting for “Rate Cuts.” Here's How to Build an 8% Yield Portfolio Even if the Fed Holds Rates in December
The post Stop Waiting for “Rate Cuts.” Here's How to Build an 8% Yield Portfolio Even if the Fed Holds Rates in December appeared first on 24/7 Wall St.....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
